Navigation Links
Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
Date:7/7/2013

AARHUS, Denmark, July 4, 2013 /PRNewswire/ --

Unisense FertiliTech, world leader in time-lapse technology for IVF announce they will present a large scale analysis of embryo development variables which are linked to implantation potential at the European Society of Human Reproduction and Endocrinology (ESHRE) in London July 7th until 10th.  These results will be presented at the Unisense FertiliTech exhibit.

     (Logo: http://photos.prnewswire.com/prnh/20130704/626274)

Many clinics using the EmbryoScope™ time-lapse system provide information about embryo development and clinical treatment outcome to Unisense FertiliTech´s database. This database is the largest of its kind and contains detailed information on embryo development characteristics in relation to implantation and successful pregnancy.  

Based on an agreement with 40 clinics comprising 12,000 transferred embryos, a detailed analysis of 8,000 embryos with known implantation outcome was performed.  The analysis revealed clear variables, which could be used to help select better embryos for day 2, 3 or 5 transfer. Furthermore, the strength of the aneuploidy risk algorithm, recently reported by the CARE Fertility group in the journal RBMonline (Campbell et al, Reprod.Biomed. Online 2013 May; 26(5):477-85.) was tested against a large dataset and it confirmed the findings.  

Bjørn Molt Petersen and Mette Lægdsmand, data analysis experts at FertiliTech, state "Although this analysis appears to show convincing trends that are linked to embryo development potential, the analysis also reveals the impact of different culture conditions and practices between clinics. This means that the actual criteria for good embryo quality needs to be individually validated prior to use".  

Unisense FertiliTech who celebrates 10 years in developing innovative technologies to improve embryo selection in the IVF laboratory has developed and manufactures the EmbryoScope™ time-lapse system.  The system was cleared for clinical use in Europe in 2009 and is the only time-lapse system which is FDA cleared for clinical use in the USA.  The technology is used in routine clinical practice by more than 275 clinics worldwide and has been used in approximately 60,000 treatment cycles. It is estimated that more than 10,000 babies have been born using the EmbryoScope™ system.  

In order to allow clinics to utilize the full potential of time-lapse technology, Unisense FertiliTech continues to develop embryo analysis software to improve outcomes in IVF.   Chief Scientific Officer Niels Birger Ramsing states "very early on, we recognized the need for software tools which will allow clinics to customize their own evaluation models in their clinics, that is why we are at the forefront of delivering such tools to help our customers make the best decisions".

About Unisense FertiliTech A/S:

Unisense FertiliTech A/S was founded in 2003 to develop technology to improve human embryo assessment in assisted reproduction. Unisense FertiliTech has developed, and manufactures the EmbryoScope™ time- lapse system, facilitating improved IVF treatment, flexible work routines and effective communication through comprehensive documentation of embryo development and evolving improvements in selection. The System is FDA 510(k) cleared and CE marked as a Class II medical device.

Our Mission is to help infertile couples achieve their dream of parenthood through development of novel technology, quantification and digitized documentation. "The Vision to Conceive"

Unisense FertiliTech A/S

http://www.fertilitech.com



'/>"/>
SOURCE Unisense Fertilitech A/S
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Unisense FertiliTech A/S Secures an Additional 20 Million USD in New Capital Investment
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Westport, CT (PRWEB) , ... December 09, 2016 , ... ... a small percentage of sales to a charity, it not only donates 15%-20% of ... name brands are sold at the lowest factory-permitted prices. , At inception, over 50 ...
(Date:12/9/2016)... ... 09, 2016 , ... There’s a winning streak at Voxx Analytics: the tech ... after winning the award last year as well. Employees nominate their companies for the ... Vesely pointed to the tech company’s upbeat environment as a reason. “We don’t answer ...
(Date:12/9/2016)... ... ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland Company ... Platts Global Energy for their platform technology to produce a revolutionary biobased monomer, ... Global Energy Awards, held in New York on Thursday, Dec. 8. , The ...
(Date:12/9/2016)... ... 2016 , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of ... States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete ... on to say that, “We expect interest to continue to rise as AxioMed completes ...
Breaking Biology Technology:
(Date:12/8/2016)... , Dec. 8, 2016 Market Research Future published a ... The global Mobile Biometric Security and Service Market is expected to ... 2022. Market Highlights: ... , Mobile Biometric Security ... to the increasing need of authentication and security from unwanted cyber ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... , December 7, 2016 According to a new ... Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And ... estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion ... Continue Reading ... ...
Breaking Biology News(10 mins):